312 related articles for article (PubMed ID: 31346755)
1. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
[TBL] [Abstract][Full Text] [Related]
2. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
3. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
Jin P; Bai M; Liu J; Yu J; Meng X
Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
[TBL] [Abstract][Full Text] [Related]
5. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer.
Seban RD; Rouzier R; Latouche A; Deleval N; Guinebretiere JM; Buvat I; Bidard FC; Champion L
Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3560-3570. PubMed ID: 33774685
[TBL] [Abstract][Full Text] [Related]
6.
Wong A; Callahan J; Keyaerts M; Neyns B; Mangana J; Aberle S; Herschtal A; Fullerton S; Milne D; Iravani A; McArthur GA; Hicks RJ
Cancer Imaging; 2020 May; 20(1):36. PubMed ID: 32408884
[TBL] [Abstract][Full Text] [Related]
7. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
[TBL] [Abstract][Full Text] [Related]
8. Pre-Therapeutic Total Lesion Glycolysis on [
Mayerhoefer ME; Staudenherz A; Kiesewetter B; Weber M; Simonitsch-Klupp I; Gibbs P; Dolak W; Lukas J; Raderer M
Mol Imaging Biol; 2019 Dec; 21(6):1192-1199. PubMed ID: 30847823
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Values of Baseline
Zhou Y; Zhang X; Qin H; Zhao Z; Li J; Zhang B; Sang S; Wu Y; Deng S
Biomed Res Int; 2020; 2020():9746716. PubMed ID: 32185229
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
12. Can physiologic colonic [
Sachpekidis C; Stein-Thoeringer CK; Kopp-Schneider A; Weru V; Dimitrakopoulou-Strauss A; Hassel JC
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3709-3722. PubMed ID: 37452874
[TBL] [Abstract][Full Text] [Related]
13. FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy.
Flaus A; Habouzit V; De Leiris N; Vuillez JP; Leccia MT; Perrot JL; Prevot N; Cachin F
Sci Rep; 2021 Sep; 11(1):18795. PubMed ID: 34552135
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer.
Seban RD; Assie JB; Giroux-Leprieur E; Massiani MA; Soussan M; Bonardel G; Chouaid C; Playe M; Goldfarb L; Duchemann B; Girard N; Champion L
Ann Nucl Med; 2020 Dec; 34(12):968-974. PubMed ID: 33070295
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment 18F-FDG-PET/CT parameters as biomarkers for progression free survival, best overall response and overall survival in metastatic melanoma patients undergoing first-line immunotherapy.
Peisen F; Gerken A; Dahm I; Nikolaou K; Eigentler T; Amaral T; Moltz JH; Othman AE; Gatidis S
PLoS One; 2024; 19(1):e0296253. PubMed ID: 38180971
[TBL] [Abstract][Full Text] [Related]
16. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795
[TBL] [Abstract][Full Text] [Related]
17. Assessing immune organs on
Prigent K; Lasnon C; Ezine E; Janson M; Coudrais N; Joly E; Césaire L; Stefan A; Depontville M; Aide N
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2573-2585. PubMed ID: 33432374
[TBL] [Abstract][Full Text] [Related]
18. Metabolic tumor burden on baseline
Chen S; He K; Feng F; Wang S; Yin Y; Fu H; Wang H
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1830-1839. PubMed ID: 31187163
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Bone Marrow Metabolism on Pretreatment
Nakamoto R; Zaba LC; Liang T; Reddy SA; Davidzon G; Aparici CM; Nguyen J; Moradi F; Iagaru A; Franc BL
J Nucl Med; 2021 Oct; 62(10):1380-1383. PubMed ID: 33547210
[TBL] [Abstract][Full Text] [Related]
20. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
